Two cases of delayed onset of immune‐related adverse events after discontinuation of nivolumab in patients with metastatic renal cell cancer
| Autor: | Masashi Nakayama, Tomoyuki Otsuka, Kazuo Nishimura, Yasutomo Nakai, Takako Inoue, Kenichi Kakimoto, Takatoshi Nawa, Koji Hatano, Akira Nagahara, Yoshiyuki Yamamoto |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Hepatitis
renal cell carcinoma medicine.medical_specialty medicine.drug_class business.industry Urology delayed onset Case Report Case Reports medicine.disease Gastroenterology Diseases of the genitourinary system. Urology Tyrosine-kinase inhibitor immune‐related adverse events Discontinuation Renal cell carcinoma Internal medicine medicine immune‐checkpoint inhibitor RC870-923 Nivolumab business Adverse effect Progressive disease Pneumonitis |
| Zdroj: | IJU Case Reports IJU Case Reports, Vol 4, Iss 5, Pp 326-329 (2021) |
| ISSN: | 2577-171X |
| Popis: | Introduction Delayed onset of immune-related adverse events following immune-checkpoint inhibitor discontinuation is underrecognized because of little available evidence. Case presentation A 50-year-old man with metastatic renal cell carcinoma (Case 1) and 58-year-old woman with renal cell carcinoma and retroperitoneal lymph node metastasis (Case 2) underwent nivolumab therapy. Case 1: Progressive disease forced nivolumab discontinuance after 18 months, and he underwent two courses of tyrosine kinase inhibitor therapy. immune-related adverse events of pneumonitis, hepatitis, and renal dysfunction were diagnosed 142 days after nivolumab discontinuation, and he recovered with immunosuppressive treatment. Case 2: The immune-related adverse event of pneumonitis forced nivolumab discontinuance after 14 months, and two courses of tyrosine kinase inhibitor therapy were administered. The immune-related adverse event of hepatitis was diagnosed 436 days after nivolumab discontinuation, and she recovered with immunosuppressive treatment. Conclusion Two patients with delayed onset of immune-related adverse events after nivolumab discontinuation were recovered with immunosuppressive treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text